In July 2026, regulators approved once-weekly subcutaneous Leqembi Iqlik as a day-one starting dose for early Alzheimer's disease. Eligible patients can now begin anti-amyloid treatment at home, while eligibility and safety monitoring did not change.
Leqembi, the brand name for lecanemab-irmb, is an antibody treatment that targets amyloid plaques in the brain. According to Eisai, the approval covers initiation therapy, with initiation autoinjectors becoming available through specialty-pharmacy distribution in late August 2026 Eisai initiation announcement. The practical result is fewer infusion-center visits, but the same medical workup before and during treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the new starting dose involves
- Who remains eligible
- What safety monitoring still requires
- What starting at home still involves
What the new starting dose involves
The initiation regimen is 500 mg once weekly, given as two consecutive 250 mg autoinjector injections. According to Eisai via PR Newswire, each injection takes about 15 seconds and is designed for at-home use Eisai treatment details.
This is a shift from the earlier sequence. Subcutaneous Leqembi Iqlik was first approved only for maintenance at 360 mg weekly after 18 months of intravenous infusions. Patients may now receive either IV or subcutaneous treatment during initiation and maintenance, and may switch routes under medical direction.
Who remains eligible
Eligibility did not expand with the new route. Treatment remains for adults with mild cognitive impairment or mild dementia due to early Alzheimer's disease, with confirmed amyloid pathology. According to the FDA, this is the same population studied in the confirmatory trial supporting traditional approval FDA approval notice.
Amyloid confirmation still comes first. A positive amyloid PET scan or cerebrospinal fluid test is required before prescribing. Cognitive stage, other medical conditions, and medication review also shape whether treatment fits.
What safety monitoring still requires
Safety warnings did not loosen. The label retains a boxed warning for amyloid-related imaging abnormalities, meaning brain swelling or bleeding that may cause headache, confusion, dizziness, vision changes, or no symptoms.
Doctors are advised to test for ApoE ε4 genetic risk before starting treatment. MRI scans are scheduled before treatment and during early months to detect swelling or bleeding. Patients using anticoagulants need added review because bleeding risk rises.
What starting at home still involves
Home dosing removes infusion appointments, but not clinic oversight. Families still need a diagnosis visit, amyloid testing, genetic-risk counseling, MRI appointments, and injection training. Support at home matters for storing autoinjectors, keeping the weekly schedule, and reporting side effects quickly.
Supportive evidence came from the Clarity AD extension. Subcutaneous dosing showed comparable drug exposure and 14% greater amyloid clearance at six months than IV dosing, with clinical benefit maintained. Scheduled MRIs, symptom checks, and follow-up visits remain mandatory even when injections go well.
You Might Also Like
- Injection Training for the 2026 At-Home Leqembi Regimen: What Changed and What Did Not for People With Early Alzheimer’s
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: What Is Established and What Remains Uncertain for Younger-Onset Alzheimer’s Families
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What Is Established and What Remains Uncertain for Younger-Onset Alzheimer’s Families
